Search
Search
Diana V. Do, MD; David S. Chin Yee, MD; Esther L. Kim, MD; Charles C. Wykoff, MD, PhD
Show Description +
What is the relationship between vision and anatomy in patients with Wet AMD and DME? How does this relationship affect decisions about whether to extend treatment intervals? And, how is treatment durability related to visual acuity and anatomic outcomes? Join roundtable moderator Diana V. Do, MD, and panelists David S. Chin Yee, MD; Esther L. Kim, MD; and Charles C. Wykoff, MD, PhD, as they explore what characteristics could make a therapy durable and examine which anatomic and visual acuity criteria should be met in order to consider extending treatment intervals for patients.
Posted: 11/13/2023
Diana V. Do, MD; David S. Chin Yee, MD; Esther L. Kim, MD; Charles C. Wykoff, MD, PhD
What is the relationship between vision and anatomy in patients with Wet AMD and DME? How does this relationship affect decisions about whether to extend treatment intervals? And, how is treatment durability related to visual acuity and anatomic outcomes? Join roundtable moderator Diana V. Do, MD, and panelists David S. Chin Yee, MD; Esther L. Kim, MD; and Charles C. Wykoff, MD, PhD, as they explore what characteristics could make a therapy durable and examine which anatomic and visual acuity criteria should be met in order to consider extending treatment intervals for patients.
Posted: 11/13/2023
Contemporary Challenges to Treating Wet Age-related Macular Degeneration and Diabetic Macular Edema
About Regeneron
Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.
Visit us online: regeneron.com
Follow Regeneron
Copyright © 2023 Regeneron Pharmaceuticals Inc. All rights reserved.
10/2023
US.OPH.23.09.0002
%20(1)_1704487948.png?auto=compress,format&w=180)
_1704488209.png?auto=compress,format&w=180)
_1704488282.png?auto=compress,format&w=180)